termsTerm
Smouldering myeloma / MGUS
Early plasma-cell conditions with no organ damage; most never progress, but high-risk smouldering disease is now sometimes treated.
MGUS progresses at ~1% per year; smouldering myeloma at ~10% per year for five years, higher with the 20/2/20 criteria (M-protein >2 g/dL, >20% plasma cells, free light chain ratio >20). Lenalidomide (E3A06) and daratumumab (AQUILA, 2024: progression HR 0.49) delay progression in high-risk smouldering disease; whether to treat remains debated. iStopMM (Iceland) is screening a whole population.
Clinical: what this kind of term is about · animated schematic, not to scale
Category
Clinical